Next Article in Journal
Experience Applying the Guidelines for Reporting Reliability and Agreement Studies (GRRAS) Indicated Five Questions Should Be Addressed in the Planning Phase from a Statistical Point of View
Next Article in Special Issue
Imaging as a Personalized Biomarker for Prostate Cancer Risk Stratification
Previous Article in Journal
Diagnosis of Newly Delivered Mothers for Periodontitis with a Novel Oral-Rinse aMMP-8 Point-of-Care Test in a Rural Malawian Population
Previous Article in Special Issue
Genome-Based Classification and Therapy of Prostate Cancer
Article Menu
Issue 4 (December) cover image

Export Article

Open AccessViewpoint
Diagnostics 2018, 8(4), 68;

Liquid Biopsy Potential Biomarkers in Prostate Cancer

Department of Urology, Research Laboratory, University Leipzig, D-04103 Leipzig, Germany
Author to whom correspondence should be addressed.
Received: 9 August 2018 / Revised: 12 September 2018 / Accepted: 14 September 2018 / Published: 21 September 2018
(This article belongs to the Special Issue Diagnostic Biomarkers in Prostate Cancer)
Full-Text   |   PDF [1112 KB, uploaded 21 September 2018]   |  


Prostate cancer (PCa) is the second most common cancer in men worldwide with an incidence of 14.8% and a mortality of 6.6%. Shortcomings in comprehensive medical check-ups in low- and middle-income countries lead to delayed detection of PCa and are causative of high numbers of advanced PCa cases at first diagnosis. The performance of available biomarkers is still insufficient and limited applicability, including logistical and financial burdens, impedes comprehensive implementation into health care systems. There is broad agreement on the need of new biomarkers to improve (i) early detection of PCa, (ii) risk stratification, (iii) prognosis, and (iv) treatment monitoring. This review focuses on liquid biopsy tests distinguishing high-grade significant (Gleason score (GS) ≥ 7) from low-grade indolent PCa. Available biomarkers still lack performance in risk stratification of biopsy naïve patients. However, biomarkers with highly negative predictive values may help to reduce unnecessary biopsies. Risk calculators using integrative scoring systems clearly improve decision-making for invasive prostate biopsy. Emerging biomarkers have the potential to substitute PSA and improve the overall performance of risk calculators. Until then, PSA should be used and may be replaced whenever enough evidence has accumulated for better performance of a new biomarker. View Full-Text
Keywords: prostate cancer (PCa); biomarkers; liquid biopsy; diagnosis high-grade PCa; risk stratification; risk calculators prostate cancer (PCa); biomarkers; liquid biopsy; diagnosis high-grade PCa; risk stratification; risk calculators

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Neuhaus, J.; Yang, B. Liquid Biopsy Potential Biomarkers in Prostate Cancer. Diagnostics 2018, 8, 68.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Diagnostics EISSN 2075-4418 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top